

The University of Auckland, The University of Waikato & NZSSD

PRESENTS

PACIFIC DIABETES MANAGEMENT COURSE

with support & facilitation from  Aotearoa Diabetes Collective

Your session will start shortly

Welcome to the 2025
Pacific Diabetes Management Course



1

Housekeeping

- Please stay on **mute** during the webinar
- You can ask questions anytime during the webinar using the **Q+A function**
 - Any question is fine and will be answered at the end of the session
 - You can **upvote** questions that you want answered first
 - You can also ask questions verbally at the end of the session – please use the hand function if able
- **Confidentiality is a must** – These sessions will be recorded and available in a public format
- **Respect** one another
 - This is a collaborative, non-judgemental learning environment for everyone

Pacific Diabetes Management Course 2025

2

The University of Auckland, The University of Waikato & NZSSD

PRESENTS

PACIFIC DIABETES MANAGEMENT COURSE

with support & facilitation from  Aotearoa Diabetes Collective

Webinar 1.

**Lifestyle interventions,
Metformin + Vildagliptin**



3

Lifestyle management

- Cornerstone of management of type 2 diabetes + remains important at all times
- Should ideally develop a personalised weight management plan if overweight
 - 5% sustained total body weight loss results in improvements in all metabolic parameters
 - 10-15% sustained total body weight loss typically required to achieve 'remission' of T2D
- Consists of 4 key areas of management:
 - Healthy eating
 - Physical activity
 - Healthy sleep
 - Education + support
- Refer to structured education programmes and/or lifestyle intervention if available

Pacific Diabetes Management Course 2025

4

Other key areas of lifestyle management

- Smoking cessation + alcohol reduction
- Screening for depression + diabetes distress
 - Screening tools such as PHQ2 + DDS2 can be useful
- Contraception
- Ensuring flu/COVID vaccinations + malignancy screening up to date

Pacific Diabetes Management Course 2025

5

Healthy eating

Pacific Diabetes Management Course 2025

6

Pacific Diabetes Management Course 2025

8

Pacific Diabetes Management Course 2025

8

Pacific Diabetes Management Course 2025

9

Resources embedded in NZSSD guidance

12



13



14

Dietary strategies in managing T2D

- Many dietary strategies have been used to treat T2D including:
 - Very low carbohydrate (ketogenic) diet
 - Intermittent fasting e.g. 5:2 diet, time restricted feeding, weekly water fasting etc.
 - Low GI diet
 - Mediterranean diet
 - Plant-based diets
 - Commercial weight loss programmes etc.
- No conclusive evidence to suggest any of these dietary strategies any better than any other
- But only **Mediterranean + plant-based diets** shown to ↓ HbA1c, weight + CV risk at 2yrs
 - Other diets appear safe + effective in short-term

Pacific Diabetes Management Course 2025

15

Tips on the best approach

- Provide evidence-based advice but patient preference, tolerance + income etc. often governs approach
- Ensure adequate nutrition particularly in youth, pregnancy, breastfeeding + the elderly
- **Ensure patient safety with change in diets**
 - Do not use empagliflozin when carbohydrate intake < 130 g per day
 - Monitoring of glucose levels is essential for safety in patients on insulin and/or sulfonylureas
 - **Consider stopping prandial insulin + sulfonylureas & + basal insulin by up to 50% on days of fasting**
 - Consider reducing antihypertensives + diuretics + increasing allopurinol if significant weight loss
- **Consider VLED intervention in early type 2 diabetes and prediabetes**
 - Appears best dietary strategy in achieving 'remission' of T2D

✦ The 'best approach' is likely whatever strategy works!

Pacific Diabetes Management Course 2025

16

Physical activity

Pacific Diabetes Management Course 2025

17

Physical activity

- **Current recommendations for physical activity in people with T2D are:**
 - 150 mins of ≥ moderate intensity aerobic exercise on ≥ 3 days per week with ≤ 2 days without exercise
 - Resistance exercise ≥ 2 days per week
 - Sitting for ≤ 30 mins
 - May need to reduce intensity and/or duration due to comorbidities e.g. heart disease, co-morbidities
- **Most people will not meet recommendations → aim for as much movement as possible**
 - 5-6 mins of brisk walking per day is associated with an additional 4 years of life
 - Moving briskly with everyday activities is associated with up to 50% reductions in CV events
 - Stretching alone significantly reduces glucose levels

Pacific Diabetes Management Course 2025

18

Physical activity continued...

• Ensure patient safety during exercise

- May need to reduce doses of insulin and/or sulfonylureas around exercise if the person has tight glycaemia
- Ensure adequate footwear + carry treatment for hypoglycaemia

Pacific Diabetes Management Course 2025

19



Pacific Diabetes Management Course 2025

20

Healthy sleep

Pacific Diabetes Management Course 2025

21

Healthy sleep

- **Sleep disorders** are common in T2D – associated with increases in glucose levels + weight
 - >50% of people with T2D have OSA → treatment of OSA significantly improves glucose levels
- **Optimal length of sleep** on glucose levels + body weight is **6-8 hours per night**
 - Weekend or 'catch-up' sleep does not fully reverse deleterious effects of insufficient sleep
- **Discuss** healthy sleep + sleep hygiene **with all with T2D**
- **Screen** for OSA + other sleep disorders where appropriate

Pacific Diabetes Management Course 2025

22

Education & support

Pacific Diabetes Management Course 2025

23

Education & support

- **Critical** in enabling **self-management** + getting people with diabetes to reach their **targets**
- Education should be **culturally appropriate** + ideally involve **the whole family**
- All patients should ideally have access to a **glucometer** + **testing strips**
- Provide **written information** on living well with diabetes including:
 - Diabetes + healthy food choices, Diabetes + physical activity + Staying well with diabetes
 - Sick day management
 - Management of hypoglycaemia & diabetes + driving if starting insulin and/or sulfonylureas

Pacific Diabetes Management Course 2025

24

Education & support

- Consider best model of care within current resources to provide education
 - E.g. individual versus group education, separate nurse appointment, use of resources etc.
- Use local self-management programmes and other local services if available
 - Health coaches + health navigators
 - Social workers
 - Dietitians
 - Psychologists
- Integrate care with traditional Pacific medicine if family wish
- Screen for depression + diabetes distress → consider treatment as required

Pacific Diabetes Management Course 2025

25

Glucose lowering therapies in Aotearoa New Zealand

Pacific Diabetes Management Course 2025

26


Glucose lowering therapies in Aotearoa New Zealand

Oral	Injectable
- Metformin - Empagliflozin (Jardiance) - Vildagliptin (Galvus) - Pioglitazone (Vexazone) - Acarbose (Accarb) - Sulfonylureas (Glipizide/Gliclazide)	- GLP1Ra - Dulaglutide (Trulicity) - weekly - Liraglutide (Victoza) - daily - Semaglutide (Wegovy) - weekly - Insulin - Basal insulin - Prandial insulin - Bolus insulin - Premixed or co-formulated insulin - Correction insulin

Pacific Diabetes Management Course 2025

27

The 'ominous octet'



Thatcher, Am J Card 2017

Pacific Diabetes Management Course 2025

28

Metformin

Pacific Diabetes Management Course 2025

29

Metformin

- Biguanide that reduces hepatic glucose output + insulin resistance
- Typically leads to 1-2 kg weight loss + **reduces CV disease independently of glucose levels**
 - Reduces progression of T2D & likely reduces solid cancers + prolongs survival
- Maximal mean decrease in HbA1c ~ 15 mmol/mol + **does not cause hypoglycaemia alone**
- **1st line management with lifestyle management** for all patients with T2D + prediabetes
 - Start together at diagnosis but still beneficial to introduce at any time
 - Add another agent if HbA1c > 64 mmol/mol at diagnosis OR if HbA1c above target at 3 months

Pacific Diabetes Management Course 2025

30

Metformin

- **GI adverse effects usually preventable if start low + slow – even in those who are 'intolerant'**
 - Start at 250 – 500 mg once or twice daily with food
 - Can increase at least weekly to 2g per day or maximal tolerated dose
- **Galvumet + Jardimet seem to be much better tolerated than metformin alone**
 - Extended release or liquid metformin not available but **pharmacies can make metformin suspension**
- **No benefit in doses > 2 g per day** + need to reduce doses with declining renal function
 - eGFR 30 – 45 mL/min → maximal dose 1000 mg per day
 - eGFR 15 – 29 mL/min → maximal dose 500 mg per day
 - eGFR < 15 mL/min → need to stop metformin

Pacific Diabetes Management Course 2025

31

Metformin

- Risk of lactic acidosis likely negligible
 - But still safer to **not use in end-stage liver, renal or heart failure**
- Risk of contrast-induced renal injury with metformin also likely negligible
 - Guidance still recommends withholding metformin if eGFR < 30 mL/min
- Only need to monitor vitamin B₁₂ levels if **symptomatic of B₁₂ deficiency** e.g. neuropathy
- Metformin + insulin are the only known safe glucose-lowering therapies in pregnancy + breastfeeding
 - **Beware that metformin (and GLP1RA) may induce ovulation so consider contraception**

Pacific Diabetes Management Course 2025

32

Why do you start Metformin at diagnosis of T2D?

Pacific Diabetes Management Course 2025

33

Starting metformin at diagnosis

- **Reduces progression of T2D**
 - Ideally should be started in high-risk prediabetes
- **Reduces CV disease** + likely solid cancers independently of effect on glucose levels
- Aids **weight loss** + **does not cause hypoglycaemia**
- Reduces clinical inertia

Pacific Diabetes Management Course 2025

34

Vildagliptin (Galvus)

Pacific Diabetes Management Course 2025

35

Vildagliptin

- Inhibits the enzyme DPP-IV prolonging the half-life of endogenous GLP-1
 - Increases glucose-dependent insulin secretion → **does not cause hypoglycaemia alone**
 - Decreases glucagon secretion
 - Increases incretin effect → decreased gastric emptying + neurotransmitter dysfunction → decreased appetite
- Weight neutral + no known independent benefits on reducing CVD or renal disease
 - **Only agent known to date in combination with metformin to reduce progression to insulin**
- Normal dose is 50 mg twice daily either alone (Galvus) or in combination with metformin (Galvumet)
 - **Reduce dose of vildagliptin to 50 mg daily once eGFR < 50 mL/min**

Pacific Diabetes Management Course 2025

36

Vildagliptin

- Mean maximal reduction in HbA1c is only 5 – 10 mmol/mol
- Generally very well tolerated but adverse effects include:
 - Nausea, anorexia, vomiting + diarrhoea (much milder than GLP1Ra)
 - Nasopharyngitis
 - Hepatotoxicity → consider stopping if ALT or AST > 2.5 x ULN without explanation (repeat LFTs with HbA1c)
 - Rare significant skin reactions e.g. bullous pemphigoid + Stevens Johnson Syndrome
- Do not use in:
 - T1D, pregnancy, breastfeeding, < 18 years of age and/or unstable CHF as no safety data
 - Severe gastrointestinal disease, medullary thyroid cancer or pancreatitis without explanation
 - **Vildagliptin is redundant when on GLP1Ra** e.g. dulaglutide or liraglutide

Pacific Diabetes Management Course 2025

37

The ‘ominous octet’

Pacific Diabetes Management Course 2025

38

Summary of glucose lowering therapies

	Metformin	Vildagliptin
Risk of hypoglycaemia	Rare	Rare
Mean maximal HbA1c ↓	15	5-10
Independent cardio-renal benefits	Yes	No
Effect on weight	↓	↔

Pacific Diabetes Management Course 2025

39

What are the take home messages?

Pacific Diabetes Management Course 2025

40

Take home messages

- **Lifestyle management + metformin** remain first line management in all stages of T2D
- **Weight loss if overweight** is critical with **lifestyle changes** encompassing:
 - Healthy eating + sleep
 - Physical activity
 - Education + support
- **The best dietary strategy** is whatever works for the individual patient!
- **Vildagliptin + other glucose lowering therapies** are often required in managing T2D
 - Hypoglycaemia will only occur with sulfonylureas and/or insulin

Pacific Diabetes Management Course 2025

41

Upcoming webinars

- 1 **Lifestyle management, Metformin & Vildagliptin**
Host: Wednesday September 10th at 5pm
Cook Islands: Monday September 15th at 5pm
Auckland NZ: Tuesday September 16th at 5pm
[Join us](#)
- 2 **Sulfonylureas & Insulin - Management of Hypoglycaemia**
Host: Monday September 15th at 5pm
Cook Islands: Monday September 15th at 5pm
Auckland NZ: Tuesday September 16th at 5pm
[Join us](#)
- 3 **New Diabetes Medication, Technology & Management algorithms**
Host: Thursday September 18th at 5pm
Cook Islands: Monday September 22nd at 5pm
Auckland NZ: Tuesday September 23rd at 5pm
[Join us](#)
- 4 **Diabetes, Blood Pressure & Lipid Targets - Management**
Host: Thursday September 18th at 5pm
Cook Islands: Monday September 22nd at 5pm
Auckland NZ: Tuesday September 23rd at 5pm
[Join us](#)
- 5 **Diabetes and Risk-Free Management, Driving & Pregnancy**
Host: Thursday October 2nd at 5pm
Cook Islands: Monday October 6th at 5pm
Auckland NZ: Tuesday October 7th at 5pm
[Join us](#)
- 6 **Management of Complications Related to Diabetes**
Host: Thursday October 2nd at 5pm
Cook Islands: Monday October 6th at 5pm
Auckland NZ: Tuesday October 7th at 5pm
[Join us](#)
- 7 **Insulin Management of Diabetes**
Host: Thursday October 2nd at 5pm
Cook Islands: Monday October 6th at 5pm
Auckland NZ: Tuesday October 7th at 5pm
[Join us](#)

Pacific Diabetes Management Course 2025

42

Case: 70 yr old Tongan female

Presentation – new patient to clinic, latest HbA1c is 7.5, does not want to increase insulin due to weight gain but has multiple drug intolerances and declines referral to dietitian or diabetes clinic

- **Diabetes Hx:** Type 2 diabetes with multiple drug intolerances (pioglitazone & metformin cause nausea, empagliflozin causes urinary frequency, dulaglutide causes nausea, joint pains and thin hair)
- **Diabetes related comorbidities:** diabetic eye disease (moderate non-proliferative retinopathy and unilateral non-fovea macula oedema)
- **Diabetes related medications:** NovoMix 30 – 38 units bd
- **Other relevant medications:** candesartan 4mg od
- **Assessment:**
 - Measures – BMI 34; BP 150/70
 - Labs – HbA1c 7.5; LDL 3.9, eGFR 67; ACR normal
- **Question/s:**
 - What are the next steps to improve HbA1c?

Pacific Diabetes Management Course 2025

43

Discussion

Pacific Diabetes Management Course 2025

44
